Novo Nordisk (NVO) PT Lowered to $45 at BMO Capital Following 'Soft' Guide
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman lowered the price target on Novo Nordisk (NYSE: NVO) to $45.00 (from $57.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
